Welcome to our dedicated page for Genpact SEC filings (Ticker: G), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Genpact's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Genpact's regulatory disclosures and financial reporting.
Vanguard Portfolio Management reports beneficial ownership of 8,705,834 shares of Genpact Ltd Common Stock, representing 5.12% of the class. The filing shows Vanguard Portfolio Management has sole dispositive power over 8,705,834 shares and sole voting power for 62,760 shares as reported on 03/31/2026.
The disclosure states these holdings reflect securities managed by Vanguard Portfolio Management LLC and affiliated business divisions, including shares held for Vanguard funds and client accounts.
Genpact Limited held its 2026 annual general meeting on April 23, 2026, where shareholders voted on director elections, executive pay and the auditor appointment. All ten board nominees were elected, each receiving over 128 million votes in favor, with broker non-votes of 9,589,913 for each director.
Shareholders approved, on a non-binding advisory basis, compensation for named executive officers, with 125,882,016 votes in favor, 9,847,642 against and 165,272 abstentions, plus 9,589,913 broker non-votes. They also approved appointing KPMG Assurance and Consulting Services LLP as independent registered public accounting firm for fiscal 2026, with 134,484,965 votes in favor, 10,944,301 against and 55,577 abstentions.
Hinshaw John M reported acquisition or exercise transactions in this Form 4 filing.
Genpact LTD director John M. Hinshaw received an equity award in the form of restricted share units. He was granted 6,521 unvested RSUs, each entitling him to one common share in the future. Subject to his continued service, these RSUs will fully vest on December 31, 2026 and will be settled in common shares on December 31, 2027. Following this grant, he holds 8,855 common shares directly.
Morken CeCelia reported acquisition or exercise transactions in this Form 4 filing.
Genpact Ltd director CeCelia Morken received an equity grant in the form of restricted share units (RSUs). The award covers 6,521 common shares granted at no cash cost under the Genpact Limited 2017 Omnibus Incentive Compensation Plan. Each RSU entitles her to one common share at a future date, subject to continued service. The RSUs will fully vest on December 31, 2026 and will be settled in common shares on December 31, 2027. Following this grant, she directly holds 64,281 common shares.
Genpact LTD director Carol Lindstrom received an equity award of 6,521 common-share RSUs. The grant, priced at $0.00 per unit as compensation, increases her direct holdings to 27,706 common shares after the award. Each restricted share unit entitles her to one common share at a future date.
According to the award terms, all RSUs will fully vest on December 31, 2026, assuming she continues in service, and will be settled in common shares on December 31, 2027. This is a non-market, compensation-related acquisition rather than an open-market purchase.
Gangestad Nicholas C reported acquisition or exercise transactions in this Form 4 filing.
Genpact LTD director Nicholas C. Gangestad received an equity grant in the form of restricted share units. He was awarded 6,521 unvested RSUs, each representing one common share at a future date, increasing his direct holdings to 15,334 common shares after the award.
The RSUs were granted under the Genpact Limited 2017 Omnibus Incentive Compensation Plan. Subject to his continued service, the entire RSU award will vest on December 31, 2026 and will be settled in common shares on December 31, 2027, aligning his compensation further with long-term shareholder interests.
Subaiya Thimaya K. reported acquisition or exercise transactions in this Form 4 filing.
Genpact LTD director Subaiya Thimaya K. received a compensation grant of 6,521 unvested restricted share units (RSUs) of common shares at no cash cost. Each RSU represents one future Genpact common share. Subject to continued service, all RSUs will vest on December 31, 2026 and be settled in common shares on December 31, 2027. Following this award, the director holds 8,541 common shares directly, including the unvested RSUs reported in this filing.
Verdi Mark A reported acquisition or exercise transactions in this Form 4 filing.
Genpact LTD director Mark A. Verdi reported a compensation-related share grant. He received 6,521 unvested restricted share units (RSUs), with each RSU representing one common share granted at no cash cost. These RSUs fully vest on December 31, 2026 and will be settled in common shares on December 31, 2027. Following this award, Verdi directly holds 71,526 common shares.
Genpact Limited director Brian Mark Stevens received an equity award in the form of restricted share units. He acquired 6,521 common shares at a price of $0.00 per share through a grant classified as a non-derivative award. Following this award, his direct holdings increased to 36,619 common shares.
The grant represents unvested restricted share units (RSUs) under the Genpact Limited 2017 Omnibus Incentive Compensation Plan. Each RSU entitles him to one common share. Subject to his continued service, the RSUs will fully vest on December 31, 2026 and will be settled in common shares on December 31, 2027.
Conigliaro Laura reported acquisition or exercise transactions in this Form 4 filing.
Genpact LTD director Laura Conigliaro received an equity award of 6,521 unvested restricted share units (RSUs). The grant was made in the form of common share RSUs under the Genpact Limited 2017 Omnibus Incentive Compensation Plan as part of her director compensation.
Each RSU entitles her to receive one common share at a future date. The RSUs are scheduled to fully vest on December 31, 2026, assuming she continues in service, and will be settled in common shares on December 31, 2027. Following this grant, she directly holds 79,337 common shares.